Press Releases

Date	Title
July 19, 2018	Oncobiologics Completes Exchange of Series A Convertible Preferred Stock for Newly Created Series A-1 Convertible Preferred Stock CRANBURY, N.J. , July 19, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) today announced that, on July 18, 2018 , the Company completed the exchange of an aggregate of 58,735 shares of voting Series A Convertible Preferred Stock (the “Series A”) held by GMS Tenshi Holdings Pte.
July 11, 2018	Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements CRANBURY, N.J. , July 11, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) today announced that, on July 10, 2018 , the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with the applicable requirements for the continued listing of
June 20, 2018	Oncobiologics Announces Conversion of Majority of Series A Convertible Preferred Stock CRANBURY, N.J. , June 20, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and largest investor, has converted 80% of its Series A convertible preferred stock
June 18, 2018	Oncobiologics Announces Randy Thurman as Executive Chairman of the Board of Directors and Lawrence A. Kenyon as Interim CEO CRANBURY, N.J. , June 18, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that Pankaj Mohan , Ph.D., its Chairman and Chief Executive Officer (CEO), has stepped down as CEO and Chairman of the board with immediate effect. Dr. Mohan will remain a member of Oncobiologics’
June 13, 2018	Oncobiologics Enters into First CDMO Contract CRANBURY, N.J. , June 13, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it has entered into a Master Services Agreement (MSA) with Sonnet BioTherapeutics, Inc. , a privately held development stage biopharmaceutical company, and has officially launched its
June 8, 2018	Oncobiologics Closes Second Tranche of $15 Million Private Placement CRANBURY, N.J. , June 08, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that it has closed on the second, and final, tranche of a $15.0 million private placement of shares of its common stock and warrants that have an aggregate exercise price of
June 4, 2018	Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018 CRANBURY, N.J. , June 04, 2018 (GLOBE NEWSWIRE) -- Stelis Biopharma and Oncobiologics, Inc. (NASDAQ:ONS) today announced that they will unveil a new contract development and manufacturing (“CDMO”) effort at BIO 2018 in Boston. Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma
May 15, 2018	Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018 CRANBURY, N.J. , May 15, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today reported financial results and business highlights for its three and six months ended March 31, 2018 . Recent Highlights: Strengthened balance sheet with first closing of a $15.0 million private placement
May 14, 2018	Oncobiologics Announces $15 Million Private Placement Offering CRANBURY, N.J. , May 14, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that on May 11, 2018 , it entered into a purchase agreement with GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and largest investor,
April 17, 2018	Oncobiologics Appoints Randy Thurman to Board of Directors CRANBURY, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced the appointment of Randy Thurman to its board of directors, effective April 13, 2018 . At the same time, Oncobiologics also announced the resignation of Scott Canute as director and member of the